Glaukos has reported that the company’s net sales decreased by 46% in the second quarter of 2020 to $31.6 million, compared with $58.6 million in the same period in 2019. The decrease was driven primarily by disruptions associated with COVID-19, partially offset by contribution from the acquisition of Avedro.

"I am extremely proud of the actions, focus, and accomplishments of our employees, who have remained dedicated to advancing our key strategic objectives while navigating the unique challenges associated with the COVID-19 pandemic," said Thomas Burns, Glaukos president and chief executive officer. "We are encouraged with the initial return of elective procedures around the world and remain well-positioned to provide our essential ophthalmic therapies to our customers and their patients during the ongoing recovery period.”